GREG CUNY to Drug Discovery
This is a "connection" page, showing publications GREG CUNY has written about Drug Discovery.
Connection Strength
0.961
-
Foreword: neurodegenerative diseases: challenges and opportunities. Future Med Chem. 2012 Sep; 4(13):1647-9.
Score: 0.369
-
Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2713-9.
Score: 0.111
-
Enzymatic Characterization of ER Stress-Dependent Kinase, PERK, and Development of a High-Throughput Assay for Identification of PERK Inhibitors. J Biomol Screen. 2014 Aug; 19(7):1024-34.
Score: 0.102
-
Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO Mol Med. 2013 Jul; 5(7):1103-18.
Score: 0.097
-
Small-molecule Klotho enhancers as novel treatment of neurodegeneration. Future Med Chem. 2012 Sep; 4(13):1671-9.
Score: 0.092
-
Kinetic-based high-throughput screening assay to discover novel classes of macrophage migration inhibitory factor inhibitors. J Biomol Screen. 2010 Apr; 15(4):347-58.
Score: 0.078
-
Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett. 2018 11 01; 28(20):3356-3362.
Score: 0.035
-
Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy. J Med Chem. 2017 06 08; 60(11):4594-4610.
Score: 0.032
-
Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. Antimicrob Agents Chemother. 2014; 58(3):1603-14.
Score: 0.025
-
Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors. Anal Biochem. 2010 Sep 15; 404(2):186-92.
Score: 0.020